Malaria is one of the deadliest diseases worldwide. In 2021, the first approved malaria vaccine came to fruition, but its effectiveness remains low. New, more effective malaria vaccines are now in clinical trials, indicating that effective malaria prevention may soon be within reach. In this webinar, experts will discuss critical developments toward the next malaria vaccine.
Topics to be covered
• Using plasmodium falciparum to protect against malaria and treat chronic liver disease
• Developing a cross-species malaria vaccine to protect during pregnancy
Drug Discovery News Webinars
Stephen L. Hoffman, MD, DSc (hon)
Chief Executive and Scientific Officer, Sanaria Inc.
Hoffman is the founder and CEO of Sanaria Inc. and chairman of Protein Potential LLC, companies that develop vaccines for malaria, diarrheal diseases, COVID-19, and emerging infectious diseases. From 1980 to 2001, he was a United States Navy officer whose teams were leaders in malaria and DNA vaccine development and genomic sequencing. In 2000, Hoffman joined Celera Genomics as senior vice president of biologics to utilize genomics and proteomics to produce cancer immunotherapeutics and vaccines and initiate personalized/precision medicine. He has authored over 500 scientific publications and numerous patents and served as president of the American Society of Tropical Medicine and Hygiene and the American Committee on Tropical Medicine and Travelers Health. He is a member of the National Academy of Medicine. Hoffman has received the Weill Cornell Medical College's Distinguished Alumni Award and the Clara Southmayd Ludlow Medal from the American Society of Tropical Medicine and Hygiene for inspirational and pioneering work in tropical medicine.
Stephanie Yanow, PhD
Professor in Global Health, School of Public Health, University of Alberta
Yanow is a professor in Global Health within the School of Public Health and cross-appointed in the Department of Medical Microbiology and Immunology at the University of Alberta. She received her PhD training at McGill, University College London, and Caltech. Yanow spent eight years working at the Alberta ProvLab in diagnostics and in 2015 became a full faculty member in the School of Public Health. She leads a research program focused on different aspects of malaria, from basic pathogenesis to the development of diagnostics and vaccines. Her main research focus is on malaria infection in pregnancy. Together with her partners in Uganda, Colombia, Brazil, the United States, and Australia, Yanow is developing a novel vaccine approach to protect pregnant women in Africa from the devastating consequences of malaria infection.